Cyclic amine compound
    24.
    发明授权
    Cyclic amine compound 失效
    环胺化合物

    公开(公告)号:US07601734B2

    公开(公告)日:2009-10-13

    申请号:US11578169

    申请日:2005-04-08

    IPC分类号: A61K31/44 A61P25/18 A61P25/24

    摘要: An object of the present invention is to provide a cyclic amine compound which has a potent inhibitory effect on the binding of α2C-adrenoceptor and is useful in preventing and treating disorders attributable to α2C-adrenoceptor.The above-described object is solved by the following cyclic amine compound, etc., wherein X is O, S, SO, SO2 or NR2, etc.; R1 is a hydrogen atom, a cyano group, a carboxyl group, a C2-C13 alkoxycarbonyl group, a carbamoyl group, etc.; Ar1 and Ar2 are the same or different and each represent an aryl or heteroaryl group which may be substituted by 1 to 3 substituents and so on; ring B is a benzene ring may be substituted by 1 to 3 substituents and so on; n is an integer from 1 to 10; and p and q are the same or different and each represent an integer of 1 or 2.

    摘要翻译: 本发明的目的是提供对α2C-肾上腺素能受体的结合具有强效抑制作用的环胺化合物,可用于预防和治疗归因于α2C-肾上腺素受体的病症。 上述目的通过以下环胺化合物等来解决,其中X是O,S,SO,SO 2或NR 2等; R1是氢原子,氰基,羧基,C2-C13烷氧基羰基,氨基甲酰基等; Ar 1和Ar 2相同或不同,各自表示可被1〜3个取代基等取代的芳基或杂芳基; 环B为苯环可被1〜3个取代基取代等; n是1至10的整数; p和q相同或不同,各自表示1或2的整数。

    Cyclic Amine Compound
    25.
    发明申请
    Cyclic Amine Compound 失效
    环胺化合物

    公开(公告)号:US20070244145A1

    公开(公告)日:2007-10-18

    申请号:US11578169

    申请日:2005-04-08

    IPC分类号: A61K31/44 A61P25/18 A61P25/24

    摘要: An object of the present invention is to provide a cyclic amine compound which has a potent inhibitory effect on the binding of α2C-adrenoceptor and is useful in preventing and treating disorders attributable to α2C-adrenoceptor. The above-described object is solved by the following cyclic amine compound, etc., wherein X is O, S, SO, SO2 or NR2, etc.; R1 is a hydrogen atom, a cyano group, a carboxyl group, a C2-C13 alkoxycarbonyl group, a carbamoyl group, etc.; Ar1 and Ar2 are the same or different and each represent an aryl or heteroaryl group which may be substituted by 1 to 3 substituents and so on; ring B is a benzene ring may be substituted by 1 to 3 substituents and so on; n is an integer from 1 to 10; and p and q are the same or different and each represent an integer of 1 or 2.

    摘要翻译: 本发明的目的是提供对α2C-肾上腺素能受体的结合具有强效抑制作用的环胺化合物,可用于预防和治疗归因于α2C-肾上腺素受体的病症。 上述目的通过以下环胺化合物等来解决,其中X是O,S,SO,SO 2或NR 2等; R 1是氢原子,氰基,羧基,C 1 -C 13烷氧基羰基,氨基甲酰基等 。 Ar 1和Ar 2相同或不同,各自表示可被1至3个取代基等取代的芳基或杂芳基; 环B为苯环可被1〜3个取代基取代等; n是1至10的整数; p和q相同或不同,各自表示1或2的整数。

    1,3-Dihydro-2h-indol-2-one derivative
    26.
    发明申请
    1,3-Dihydro-2h-indol-2-one derivative 失效
    1,3-二氢-2H-吲哚-2-酮衍生物

    公开(公告)号:US20060276449A1

    公开(公告)日:2006-12-07

    申请号:US10569833

    申请日:2004-08-27

    CPC分类号: C07D403/04

    摘要: A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein R1 is a halogen atom, a C1 to C4 alkyl group, etc., and R2 is a hydrogen atom, a halogen atom, etc., or R2 is in the 6-position of the indol-2-one and R1 and R2 join together to form a C3 to C6 alkylene group, R3 is a halogen atom, a hydroxyl group, etc., and R4 is a hydrogen atom, a halogen atom, a C1 to C4 alkyl group, etc., or R4 is in the 3-position of the phenyl and R3 and R4 join together to form a methylenedioxy group, R5 is a hydrogen atom or a fluorine atom, R6 is an ethylamino group, a dimethylamino group, etc., R7 is a C1 to C4 alkoxy group, and R8 is a C1 to C4 alkoxy group), or a pharmaceutically acceptable salt of this derivative. This is a novel compound that has antagonistic activity against an aruginine-vasopressin V1b receptor.

    摘要翻译: 由式1表示的1,3-二氢-2H-吲哚-2-酮衍生物(其中R 1是卤素原子,C 1至C 1烷基, 4个烷基等,R 2是氢原子,卤原子等,或R 2 2位在6位的 吲哚-2-酮和R 1和R 2连接在一起以形成C 6 -C 6亚烷基, 亚烷基,R 3是卤素原子,羟基等,R 4是氢原子,卤原子,C 1, / SUB→C 4烷基等,或R 4在苯基的3位和R 3和R 3 连接在一起形成亚甲二氧基,R 5是氢原子或氟原子,R 6是乙氨基,二甲基氨基 基团等,R 7是C 1-4烷氧基的C 1至C 8,并且R 8是 C 1至C 4烷氧基),或该衍生物的药学上可接受的盐。 这是一种新的化合物,具有对抗葡萄糖酸加压素V1b受体的拮抗作用。

    1,3-dihydro-2H-indol-2-one derivative
    29.
    发明授权
    1,3-dihydro-2H-indol-2-one derivative 失效
    1,3-二氢-2H-吲哚-2-酮衍生物

    公开(公告)号:US07528124B2

    公开(公告)日:2009-05-05

    申请号:US10569833

    申请日:2004-08-27

    CPC分类号: C07D403/04

    摘要: A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein R1 is a halogen atom, a C1 to C4 alkyl group, etc., and R2 is a hydrogen atom, a halogen atom, etc., or R2 is in the 6-position of the indol-2-one and R1 and R2 join together to form a C3 to C6 alkylene group, R3 is a halogen atom, a hydroxyl group, etc., and R4 is a hydrogen atom, a halogen atom, a C1 to C4 alkyl group, etc., or R4 is in the 3-position of the phenyl and R3 and R4 join together to form a methylenedioxy group, R5 is a hydrogen atom or a fluorine atom, R6 is an ethylamino group, a dimethylamino group, etc., R7 is a C1 to C4 alkoxy group, and R8 is a C1 to C4 alkoxy group), or a pharmaceutically acceptable salt of this derivative. This is a novel compound that has antagonistic activity against an aruginine-vasopressin V1b receptor.

    摘要翻译: 由式1表示的1,3-二氢-2H-吲哚-2-酮衍生物(其中,R 1为卤素原子,C 1〜C 4烷基等,R 2为氢原子,卤素原子等) ,或R2为吲哚-2-酮的6-位,R 1和R 2连接在一起形成C 3〜C 6亚烷基,R 3为卤素原子,羟基等,R 4为氢原子 卤素原子,C 1〜C 4烷基等,或者R 4在苯基的3-位,R3和R4连接在一起形成亚甲二氧基,R5是氢原子或氟原子,R6是 乙基氨基,二甲基氨基等,R7为C1〜C4烷氧基,R8为C1〜C4烷氧基)或该衍生物的药学上可接受的盐。 这是一种新的化合物,具有对抗葡萄糖酸加压素V1b受体的拮抗作用。